SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
33.00    0.00 (0.00%)
Bid:
32.00
Ask:
34.00
Spread: 2.00 (6.25%)
Market Cap: £57.87m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Key Technology Validation Milestone

2 Jul 2024 07:00

RNS Number : 6870U
Ilika plc
02 July 2024
 

Ilika plc

("Ilika" or the "Company")

 

Key Technology Validation Milestone

 

Ilika ships first batch of prototype Goliath batteries to automotive customer

 

Ilika (AIM: IKA), a pioneer in solid-state battery technology, announces that it has shipped its first batch of prototype Goliath batteries for customer testing by a tier 1 automotive company.  

 

In May 2024, Ilika announced it had commenced in-house testing of its P1 Goliath prototype batteries in a customer-sponsored programme. Ilika has now shipped its first batch of P1 batteries to a customer for their external validation.

 

In November 2023, Ilika announced it had achieved its D4 development point, which is a design-freeze milestone in its Goliath roadmap upon which Ilika's first prototype for customer release, P1, is based. The P1 prototype is an intermediate milestone on Ilika's roadmap to its minimum viable product ("MVP") in 2025. The P1 prototype is a solid-state pouch cell with an NMC cathode and a silicon anode.

 

In line with the timeframe outlined when it published its last annual results in July 2023, Ilika confirms that it has successfully manufactured and tested batches of P1 pouch cells based on the D4 development point and is now engaged in a series of commercial programmes with automotive OEMs and Tier 1 companies.

 

Work is continuing on Ilika's roadmap through to MVP in CY25. Ilika's Goliath MVP, or P2 prototypes, will underpin licensing opportunities. Further detail regarding the product curve and development points can be found on page 11 of the Company's 2023 Annual Report, which is available by clicking here.

 

Graeme Purdy, Ilika CEO, stated: "Following up on the encouraging results from our P1 test programme, we are delighted to be engaging with a portfolio of interested OEMs and Tier 1 companies on commercially sponsored evaluation trials."

 

For more information contact:

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Jason Stewart, Chief Financial Officer

Panmure Liberum Limited (Nomad and Joint Broker)

Tel: 020 3100 2000

Andrew Godber, John More,

Nikhil Varghese, Josh Borlant

Joh. Berenberg, Gossler & Co. KG (Joint Broker)

Tel: 020 3207 8700

Mark Whitmore, Detlir Elezi,

Natasha Ninkov

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Nick Rome

Mob: 07748 325 236

 

About Ilika plc - https://www.ilika.com.

Ilika specialises in the developing and commercialisation of solid state batteries. The Company's mission is to rapidly develop leading-edge IP, manufacture and license solid state batteries for markets that cannot be addressed with conventional batteries due to their safety, charge rates, energy density and life limits. The Company achieves this by using ceramic-based lithium-ion technology that is inherently safe in manufacture and usage, higher thermal tolerance and easier to recycle which differentiates our products from existing batteries.

 

The Company has two product lines. Its Stereax batteries which are designed for powering miniature medical implants, industrial wireless sensors and specialist internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFERDFILIIS
Date   Source Headline
23rd Jun 202111:06 amRNSSecond Price Monitoring Extn
23rd Jun 202111:05 amRNSPrice Monitoring Extension
22nd Jun 20219:02 amRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSTrading Update & Notice of Results
8th Apr 20217:00 amRNSAppointment of Berenberg as Joint Corporate Broker
6th Apr 20217:00 amRNSGoliath manufacturing design collaboration
18th Mar 20217:00 amRNSISO Certification
4th Mar 20215:30 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSStereax Manufacturing Update
11th Feb 20214:30 pmRNSAward of Share Options
19th Jan 20214:42 pmRNSSecond Price Monitoring Extn
19th Jan 20214:36 pmRNSPrice Monitoring Extension
14th Jan 202111:07 amRNSSecond Price Monitoring Extn
14th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSHalf-year Report
12th Jan 20214:37 pmRNSPrice Monitoring Extension
11th Jan 20214:41 pmRNSSecond Price Monitoring Extn
11th Jan 20214:37 pmRNSPrice Monitoring Extension
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:37 pmRNSPrice Monitoring Extension
6th Jan 20214:42 pmRNSSecond Price Monitoring Extn
6th Jan 20214:39 pmRNSPrice Monitoring Extension
6th Jan 20212:06 pmRNSSecond Price Monitoring Extn
6th Jan 20212:01 pmRNSPrice Monitoring Extension
6th Jan 202111:06 amRNSSecond Price Monitoring Extn
6th Jan 202111:01 amRNSPrice Monitoring Extension
6th Jan 20219:06 amRNSSecond Price Monitoring Extn
6th Jan 20219:00 amRNSPrice Monitoring Extension
29th Dec 20204:36 pmRNSPrice Monitoring Extension
29th Dec 202010:04 amRNSStmnt re Share Price Movement
24th Dec 20201:06 pmRNSHolding(s) in Company
23rd Dec 20204:41 pmRNSSecond Price Monitoring Extn
23rd Dec 20204:36 pmRNSPrice Monitoring Extension
23rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:01 pmRNSPrice Monitoring Extension
23rd Dec 202011:06 amRNSSecond Price Monitoring Extn
23rd Dec 202011:01 amRNSPrice Monitoring Extension
21st Dec 202010:08 amRNSHolding(s) in Company
9th Dec 202012:42 pmRNSHolding(s) in Company
24th Nov 20205:37 pmRNSHolding(s) in Company
24th Nov 20207:00 amRNSUpdate on Stereax Manufacturing Implementation
11th Nov 20207:00 amRNSTrading Update & Notice of Results
4th Nov 20207:00 amRNSInvestor Webinar
13th Oct 20204:15 pmRNSHolding(s) in Company
23rd Sep 20207:00 amRNSFramework Agreement with UKBIC
22nd Sep 20201:50 pmRNSResult of AGM
26th Aug 20207:00 amRNSStereax® manufacturing plans update
26th Aug 20207:00 amRNSAnnual Report & Notice of AGM
14th Aug 20203:56 pmRNSHolding(s) in Company
14th Aug 20202:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.